Regeneron registers two new cemiplimab trials in skin cancer and early lung cancerSep 9Weekly roundup, 2 itemscemiplimab-rwlcRegeneron Pharmaceuticals
Biohaven advances degrader and epilepsy pipelines, reports Q2 2026 resultsAug 10Quarterly updateBHV-1300Biohaven Ltd.
Regeneron registers Phase 1 REGN17235 trial and joins Maryland-led lung cancer studyAug 7Weekly roundup, 2 itemscemiplimab-rwlcRegeneron Pharmaceuticals
Immuneering reports Q2 2026 results, MAPKeeper 301 dosing underwayAug 5Quarterly updateImmuneering Corporation
Regeneron reports Q2 2026 results, cemdisiran filings accepted, fianlimab trial missesJul 30Quarterly updatecemdisiranfianlimab
Regeneron backs two new trials: cemiplimab in transplant patients, blood cancer genetics studyJul 20Weekly roundup, 2 itemscemiplimab-rwlcRegeneron Pharmaceuticals
Sign inSign in